NCT06336005 - A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

February 10, 2025

Study Completion Date

February 17, 2025

Conditions

Healthy VolunteersCardiometabolic Diseases

Interventions

DRUG

NNC6022-0001

Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.

DRUG

Placebo (NNC6022-0001)

Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts

Trial Locations (1)

ICON - location Groningen, Groningen